ArticleHaematologica2019

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

Renate De Smedt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.